Agarikon.1 Cancer Supplement Development

Agarikon.1 Cancer Supplement Development

How We Developed Agarikon.1

Agarikon.1, a medicinal mushroom extract specially formulated to fight cancer, is a result of long-term, comprehensive research. It works in the lab, in vitro (cell cultures) and in vivo (on animal models). What separates Myko San’s Agarikon.1 from other products that contain healing mushrooms (e.g. Ganoderma lucidum, reishi; Lentinus edodes, shiitake; etc.) is that we also know our extract blend works in humans – we have conducted 3 human cohort studies during development.

In addition, we have analyzed the medical records of more than 20,000 users over a 20-year period. After a detailed follow up and statistical analysis, we have refined our products, dosage, and regimen. Repeating this process several times, we have greatly improved the efficacy. We were less dependent on guesswork or blindly following traditional advice, and more on science and experimental data. No competitor has done a similar preparation – and it shows in all comparative research.

Agarikon.1 component strongly inhibits squamous cell carcinoma.
Effects of Agarikon.1 on squamous cell carcinoma in vitro.
Left is the control; on the right a 50% concentration of a single Agarikon.1 component demonstrating a direct cytotoxic effect (killing cancer cells).
Source: Rudjer Boskovic Institute
Myko San medicinal mushroom supplements increase survival in patients with lung cancer
The comparison of metastatic non-small cell lung carcinoma survival rates: patients receiving just standard oncological therapy (ST) had much lower survival than those who used ST together with Myko San products (MT). (single blind, randomized cohort study, N=20, stage IV NSCLC lung cancer)
I. Jakopovich, New Dietary Supplements from Medicinal Mushrooms: Dr Myko San–A Registration Report, International Journal of Medicinal Mushrooms, Vol 13 i3 p.307-313, 2011
Agarikon.1 medicinal mushrooms extract blend inhibits cancer (squamous cell carcinoma and fibrosarcoma) much better than its components.
Agarikon.1 exhibits stronger cytotoxic effects in vitro on squamous cell carcinoma (SCCVII, blue bars) and fibrosarcoma (FsaR, red bars) than any of its components, as a result of synergy of active compounds. Lower bars indicate a higher percentage of destroyed cancer cells (better effect).
Source: Rudjer Boskovic Institute